179 related articles for article (PubMed ID: 8120046)
1. Identification of a novel retinoblastoma gene product binding site on human papillomavirus type 16 E7 protein.
Patrick DR; Oliff A; Heimbrook DC
J Biol Chem; 1994 Mar; 269(9):6842-50. PubMed ID: 8120046
[TBL] [Abstract][Full Text] [Related]
2. Protein domains governing interactions between E2F, the retinoblastoma gene product, and human papillomavirus type 16 E7 protein.
Huang PS; Patrick DR; Edwards G; Goodhart PJ; Huber HE; Miles L; Garsky VM; Oliff A; Heimbrook DC
Mol Cell Biol; 1993 Feb; 13(2):953-60. PubMed ID: 7678696
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus type 16 E7 protein inhibits DNA binding by the retinoblastoma gene product.
Stirdivant SM; Huber HE; Patrick DR; Defeo-Jones D; McAvoy EM; Garsky VM; Oliff A; Heimbrook DC
Mol Cell Biol; 1992 May; 12(5):1905-14. PubMed ID: 1314947
[TBL] [Abstract][Full Text] [Related]
4. Conserved region 3 of human papillomavirus 16 E7 contributes to deregulation of the retinoblastoma tumor suppressor.
Todorovic B; Hung K; Massimi P; Avvakumov N; Dick FA; Shaw GS; Banks L; Mymryk JS
J Virol; 2012 Dec; 86(24):13313-23. PubMed ID: 23015707
[TBL] [Abstract][Full Text] [Related]
5. Mutagenesis of the pRB pocket reveals that cell cycle arrest functions are separable from binding to viral oncoproteins.
Dick FA; Sailhamer E; Dyson NJ
Mol Cell Biol; 2000 May; 20(10):3715-27. PubMed ID: 10779361
[TBL] [Abstract][Full Text] [Related]
6. Structure of the human Papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor.
Liu X; Clements A; Zhao K; Marmorstein R
J Biol Chem; 2006 Jan; 281(1):578-86. PubMed ID: 16249186
[TBL] [Abstract][Full Text] [Related]
7. The human papillomavirus E7 oncoprotein and the cellular transcription factor E2F bind to separate sites on the retinoblastoma tumor suppressor protein.
Wu EW; Clemens KE; Heck DV; Münger K
J Virol; 1993 Apr; 67(4):2402-7. PubMed ID: 8445736
[TBL] [Abstract][Full Text] [Related]
8. Retinoblastoma protein binding properties are dependent on 4 cysteine residues in the protein binding pocket.
Stirdivant SM; Ahern JD; Oliff A; Heimbrook DC
J Biol Chem; 1992 Jul; 267(21):14846-51. PubMed ID: 1321820
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product.
Chellappan S; Kraus VB; Kroger B; Munger K; Howley PM; Phelps WC; Nevins JR
Proc Natl Acad Sci U S A; 1992 May; 89(10):4549-53. PubMed ID: 1316611
[TBL] [Abstract][Full Text] [Related]
10. The canine papillomavirus and gamma HPV E7 proteins use an alternative domain to bind and destabilize the retinoblastoma protein.
Wang J; Zhou D; Prabhu A; Schlegel R; Yuan H
PLoS Pathog; 2010 Sep; 6(9):e1001089. PubMed ID: 20824099
[TBL] [Abstract][Full Text] [Related]
11. Destabilization of the retinoblastoma tumor suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell cycle arrest in human keratinocytes.
Helt AM; Galloway DA
J Virol; 2001 Aug; 75(15):6737-47. PubMed ID: 11435552
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the binding of the human papillomavirus type 16 and cottontail rabbit papillomavirus E7 proteins to the retinoblastoma gene product.
Haskell KM; Vuocolo GA; Defeo-Jones D; Jones RE; Ivey-Hoyle M
J Gen Virol; 1993 Jan; 74 ( Pt 1)():115-9. PubMed ID: 8380832
[TBL] [Abstract][Full Text] [Related]
13. Three regions of the pRB pocket domain affect its inactivation by human papillomavirus E7 proteins.
Dick FA; Dyson NJ
J Virol; 2002 Jun; 76(12):6224-34. PubMed ID: 12021356
[TBL] [Abstract][Full Text] [Related]
14. The human papillomavirus type 16 E7 gene product interacts with and trans-activates the AP1 family of transcription factors.
Antinore MJ; Birrer MJ; Patel D; Nader L; McCance DJ
EMBO J; 1996 Apr; 15(8):1950-60. PubMed ID: 8617242
[TBL] [Abstract][Full Text] [Related]
15. The CXXC Zn binding motifs of the human papillomavirus type 16 E7 oncoprotein are not required for its in vitro transforming activity in rodent cells.
Braspenning J; Marchini A; Albarani V; Levy L; Ciccolini F; Cremonesi C; Ralston R; Gissmann L; Tommasino M
Oncogene; 1998 Feb; 16(8):1085-9. PubMed ID: 9519882
[TBL] [Abstract][Full Text] [Related]
16. Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells: consequences for the phenotype and E6-p53 and E7-pRB interactions.
von Knebel Doeberitz M; Rittmüller C; Aengeneyndt F; Jansen-Dürr P; Spitkovsky D
J Virol; 1994 May; 68(5):2811-21. PubMed ID: 8151752
[TBL] [Abstract][Full Text] [Related]
17. One-step purification of recombinant human papillomavirus type 16 E7 oncoprotein and its binding to the retinoblastoma gene product.
Kasher MS; Wakulchik M; Cook JA; Smith MC
Biotechniques; 1993 Apr; 14(4):630-41. PubMed ID: 8386522
[TBL] [Abstract][Full Text] [Related]
18. Positive and negative regulation of cell proliferation by E2F-1: influence of protein level and human papillomavirus oncoproteins.
Melillo RM; Helin K; Lowy DR; Schiller JT
Mol Cell Biol; 1994 Dec; 14(12):8241-9. PubMed ID: 7969161
[TBL] [Abstract][Full Text] [Related]
19. Determination of the binding affinity of different human papillomavirus E7 proteins for the tumour suppressor pRb by a plate-binding assay.
Dong WL; Caldeira S; Sehr P; Pawlita M; Tommasino M
J Virol Methods; 2001 Oct; 98(1):91-8. PubMed ID: 11543887
[TBL] [Abstract][Full Text] [Related]
20. Binding of the human E2F transcription factor to the retinoblastoma protein but not to cyclin A is abolished in HPV-16-immortalized cells.
Pagano M; Dürst M; Joswig S; Draetta G; Jansen-Dürr P
Oncogene; 1992 Sep; 7(9):1681-6. PubMed ID: 1323816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
